Status:
ACTIVE_NOT_RECRUITING
Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer
Lead Sponsor:
University of California, San Francisco
Conditions:
Prostate Cancer
Radiation Toxicity
Eligibility:
MALE
18-120 years
Brief Summary
RATIONALE: Gathering information about the Gleason score, prostate-specific antigen (PSA) level, and cancer stage from patients who have undergone radiation therapy for prostate cancer may help doctor...
Detailed Description
OBJECTIVES: * Evaluate the value of the pre-operative Gleason score, prostate-specific antigen level, and clinical stage in predicting the risk of failure and death in patients who have undergone rad...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of localized adenocarcinoma of the prostate
- Has undergone radiotherapy (external beam radiotherapy and/or brachytherapy) with or without hormonal therapy for adenocarcinoma of the prostate in the University of California, San Francisco (UCSF) Radiation Oncology Department at San Francisco General Hospital or Veterans Administration Medical Center of San Francisco between 1987 and 2006
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
February 25 1993
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2026
Estimated Enrollment :
3561 Patients enrolled
Trial Details
Trial ID
NCT00769223
Start Date
February 25 1993
End Date
January 31 2026
Last Update
March 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94143